These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 37326230)

  • 1. Safety of recent ophthalmic drugs and devices for wet macular degeneration.
    Timtim E; Weng CY; Finn AP
    Curr Opin Ophthalmol; 2023 Sep; 34(5):363-368. PubMed ID: 37326230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Biosimilar FYB201 Compared with Ranibizumab in Neovascular Age-Related Macular Degeneration.
    Holz FG; Oleksy P; Ricci F; Kaiser PK; Kiefer J; Schmitz-Valckenberg S;
    Ophthalmology; 2022 Jan; 129(1):54-63. PubMed ID: 33957183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ranibizumab Biosimilar (Razumab) vs Innovator Ranibizumab (Lucentis) in neovascular age-related macular degeneration (n-AMD)- efficacy and safety (BIRA study).
    Sharma A; Kumar N; Parachuri N; Bandello F; Kuppermann BD; Loewenstein A
    Eye (Lond); 2022 May; 36(5):1106-1107. PubMed ID: 34158653
    [No Abstract]   [Full Text] [Related]  

  • 4. Intravitreal Ranibizumab for neovascular Age-related macular degeneration in clinical practice: five-year treatment outcomes.
    Zhu M; Chew JK; Broadhead GK; Luo K; Joachim N; Hong T; Syed A; Chang AA
    Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1217-25. PubMed ID: 25205618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
    Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
    J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biosimilar SB11 versus reference ranibizumab in neovascular age-related macular degeneration: 1-year phase III randomised clinical trial outcomes.
    Bressler NM; Veith M; Hamouz J; Ernest J; Zalewski D; Studnička J; Vajas A; Papp A; Vogt G; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Oh I; Jeong H; Kim MY; Woo SJ
    Br J Ophthalmol; 2023 Mar; 107(3):384-391. PubMed ID: 34656987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of a Proposed Ranibizumab Biosimilar Product vs a Reference Ranibizumab Product for Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial.
    Woo SJ; Veith M; Hamouz J; Ernest J; Zalewski D; Studnicka J; Vajas A; Papp A; Gabor V; Luu J; Matuskova V; Yoon YH; Pregun T; Kim T; Shin D; Bressler NM
    JAMA Ophthalmol; 2021 Jan; 139(1):68-76. PubMed ID: 33211076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. StereoTactic radiotherapy for wet Age-Related macular degeneration (STAR): study protocol for a randomised controlled clinical trial.
    Neffendorf JE; Desai R; Wang Y; Kelly J; Murphy C; Reeves BC; Chakravarthy U; Wordsworth S; Lewis C; Peacock J; Uddin S; O'Sullivan JM; Jackson TL
    Trials; 2016 Nov; 17(1):560. PubMed ID: 27881184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial.
    Woo SJ; Bradvica M; Vajas A; Sagong M; Ernest J; Studnicka J; Veith M; Wylegala E; Patel S; Yun C; Orski M; Astakhov S; Tóth-Molnár E; Csutak A; Enyedi L; Kim T; Oh I; Jang H; Sadda SR
    JAMA Ophthalmol; 2023 Jul; 141(7):668-676. PubMed ID: 37289448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wet age-related macular degeneration: treatment advances to reduce the injection burden.
    Baumal CR
    Am J Manag Care; 2020 May; 26(5 Suppl):S103-S111. PubMed ID: 32479026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of the Port Delivery System with ranibizumab for neovascular age-related macular degeneration.
    Adamis AP; de Juan E
    Curr Opin Ophthalmol; 2022 May; 33(3):131-136. PubMed ID: 35266895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Treatment Modalities for Neovascular Age-Related Macular Degeneration: A Systematic Overview.
    Balatsoukas DD; Tsaousis KT; Boboridis KG; Konstas AG; Topouzis F
    Adv Ther; 2022 Jan; 39(1):5-32. PubMed ID: 34724151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
    Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
    Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness Analysis.
    Hernandez L; Lanitis T; Cele C; Toro-Diaz H; Gibson A; Kuznik A
    J Manag Care Spec Pharm; 2018 Jul; 24(7):608-616. PubMed ID: 29952707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intraocular and systemic inflammation-related cytokines during one year of ranibizumab treatment for neovascular age-related macular degeneration.
    Fauser S; Viebahn U; Muether PS
    Acta Ophthalmol; 2015 Dec; 93(8):734-8. PubMed ID: 26016605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spotlight on Faricimab in the Treatment of Wet Age-Related Macular Degeneration: Design, Development and Place in Therapy.
    Nair AA; Finn AP; Sternberg P
    Drug Des Devel Ther; 2022; 16():3395-3400. PubMed ID: 36199631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of a new ranibizumab biosimilar CKD-701 using a pro re nata treatment regimen in neovascular age-related macular degeneration: A phase 3 randomized clinical trial.
    Yoon CK; Oh J; Bae K; Park UC; Yu KS; Yu HG
    PLoS One; 2022; 17(11):e0275611. PubMed ID: 36374913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual Antagonism of PDGF and VEGF in Neovascular Age-Related Macular Degeneration: A Phase IIb, Multicenter, Randomized Controlled Trial.
    Jaffe GJ; Ciulla TA; Ciardella AP; Devin F; Dugel PU; Eandi CM; Masonson H; Monés J; Pearlman JA; Quaranta-El Maftouhi M; Ricci F; Westby K; Patel SC
    Ophthalmology; 2017 Feb; 124(2):224-234. PubMed ID: 28029445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis
    Singh R; Chauhan R; Saxena A; Shah A; Mondal L; Bakhle D; Shah C; Shah A; Deoghare S; Krishnan N; Godse N
    Indian J Ophthalmol; 2022 Aug; 70(8):3008-3014. PubMed ID: 35918962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.